Related references
Note: Only part of the references are listed.PEGylation of a glycosaminoglycan-binding, dominant-negative CXCL8 mutant retains bioactivity in vitro and in vivo
T. Gerlza et al.
CYTOKINE (2020)
Neuropeptide Y is involved in the regulation of quiescence of hematopoietic stem cells
Baris Ulum et al.
NEUROPEPTIDES (2020)
Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC
Li-Li Deng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Glucose Transporter 1 Promotes the Malignant Phenotype of Non-Small Cell Lung Cancer through Integrin β1/Src/FAK Signaling
Huanyu Zhao et al.
JOURNAL OF CANCER (2019)
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma
Jerome Biton et al.
CLINICAL CANCER RESEARCH (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer
Yudong Wang et al.
Oncotarget (2018)
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Matteo Canale et al.
CLINICAL CANCER RESEARCH (2017)
Next-generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome
F. Li et al.
CLINICAL GENETICS (2017)
CCL28 chemokine: An anchoring point bridging innate and adaptive immunity
Teena Mohan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2017)
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
Paul A. VanderLaan et al.
LUNG CANCER (2017)
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Catherine Labbe et al.
LUNG CANCER (2017)
Lung Cancer Frontline nivolumab - CheckMate 026 ends in stalemate
David Killock
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
Nobuhiro Tsuchiya et al.
ONCOIMMUNOLOGY (2017)
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
S. P. Kang et al.
ANNALS OF ONCOLOGY (2017)
Analytical Ultracentrifuge Studies of a Cytokine, Soluble Receptor Interaction: Comparison of Simulations and Experiments
Robert Wright et al.
BIOPHYSICAL JOURNAL (2016)
Long-Term OS for Patients With Advanced NSCLC Enrolled in the KEYNOTE-001 Study of Pembrolizumab
Suresh Ramalingam et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
CANCER METABOLISM Addicted to serine
Christian Frezza
NATURE CHEMICAL BIOLOGY (2016)
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate (vol 12, pg 452, 2016)
Michael E. Pacold et al.
Nature Chemical Biology (2016)
A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate
Michael E. Pacold et al.
NATURE CHEMICAL BIOLOGY (2016)
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer
Grant A. Howe et al.
PLOS ONE (2016)
Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients
Yu Sawada et al.
ONCOIMMUNOLOGY (2016)
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT
J. Yang et al.
CELL DEATH & DISEASE (2015)
Share Paper
